Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
17.75
Dollar change
+0.67
Percentage change
3.92
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y19.58% Total Holdings15 Perf Week0.51%
SponsorElevate Shares ETF Type Tagssingle-asset Return% 3Y- AUM87.44M Perf Month-4.52%
Fund Family Bond Type Tagsoptions Return% 5Y- NAV/sh Perf Quarter10.94%
Index- Average Maturity Tagsbiotechnology Return% 10Y 52W High39.10 -54.60% Perf Half Y-8.03%
Index Weighting Commodity Type Tagscovered-call Return% SI 52W Low13.60 30.51% Perf YTD20.75%
Active/Passive Quant Type Tags- Flows% 1M-0.86% Volatility5.39% 5.92% Perf Year-49.29%
Dividend TTM15.96 (89.93%) ESG Type Tags- Flows% 3M-12.56% ATR (14)1.12 Perf 3Y-
Dividend Ex-DateFeb 12, 2026 Dividend Type Sector/Theme Flows% YTD3.72% RSI (14)47.52 Perf 5Y-
Dividend Gr. 3/5Y- - Structure Type Region Flows% 1Y Beta0.40 Perf 10Y-
Expense1.27% Growth/Value SMA20-6.79% Flows% 3Y Rel Volume1.30 Prev Close17.08
Inverse/Leveraged Market Cap SMA502.82% Flows% 5Y Avg Volume161.96K Price17.75
IPOOct 24, 2023 Option/ShortYes / Yes SMA200-9.32% Trades Volume210,832 Change3.92%
YieldMax MRNA Option Income Strategy ETF seeks current income; exposure to the share price of the common stock of Moderna, Inc. ("MRNA"), subject to a limit on potential investment gains is the secondary consideration. The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.